Neola Medical Ab · OMXSTO:NEOLA
Neola Medical Ab — Q2 2024 Earnings Presentation
26 slides from Neola Medical Ab's earnings presentation, Aug 15, 2024
Slide 1: Q2 2024
Q2 2024 Published August 15 2024 ”In the second quarter we are reaching several key milestones meeting partial regulatory requirements for FDA approval. Our successful Human Factors Validation Study in the USA coupled with obtaining a CB certificate for Neola®, highlights its safe design and essenti
Slide 2: Neola Medical Presentation: CEO and CFO
Neola Medical Presentation, Hanna Sjöström Christian Gyllenberg CEO CFO Neola Medical since 2019 Neola Medical since 2022 Previous experience Previous experience 2 Neola Medical Q2, 2024
Slide 3: Neola Medical, a deep-tech company saving lives
Neola Medical a deep-tech company saving lives • Founded in 2016 based of advanced research • 10 employees based in Lund • Late-stage development of breakthrough medical device for lung monitoring • In process aiming for FDA grant for U.S. market launch in 2025-2026 Neola Medical Q2, 2024
Slide 4: Instant detection of pulmonary complications for proactive care
Instant detection of pulmonary complications for proactive care, reduced morbidity and improved quality of life Neola Medical Q2, 2024
Slide 5: Current standard of care in need of new technology
Current standard of care in need of new technology Current monitoring methods are insufficient: Neola Medical’s monitoring method: - Only give snapshots of lung status - Continuous monitoring of lungs - Slow to show results - Fast to show results (below seconds) - Handling disturbs the infant - Safe
Slide 6: One in ten babies is born too soon
One in ten babies is born too soon and may depend on neonatal intensive care for their survival Every year, more than 15 million babies are born preterm 1.1 million preterm born babies die every year. Preterm birth is the most common cause of death of children <5 years of age (after pneumonia). Resp
Slide 7: Growing and non-cyclical market
Growing and non-cyclical market Neola Medical is well positioned to benefit from favourable market trends Global neonatal respiratory device market USD million 3 001 Growing number of patients R: 5.9% 2 816 CAG 2 662 Increase in preterm births worldwide, leading to more children 2 534 developing RDS
Slide 8: Revenue streams
Revenue streams Include sales of device, disposables and service agreement One Neola® unit per baby/bed Daily change of disposable Service agreement revenue probes Neola Medical Source: BasedQ2, on2024 Pricing project findings by MCRA 2022 incl. field market research of 40 providers, 20 neonatologis
Slide 9: Huge addressable market with one Neola per baby
Huge addressable market with one Neola® per baby France United Kingdom 57,000 2,547 53,887 Preterm NICU care 1,782 Preterm babies places NICU care babies places Germany United States 66,752 Preterm 2,140 NICU care babies places § Focus market due to large number of newborns and the particularly high
Slide 10: Unlocking Exponential Revenue Potential: Neola Devices + high margin Disposables
Unlocking Exponential Revenue Potential: Neola® Devices + high margin Disposables Targeting a Total Addressable Market of 35,600 Beds (and Growing) in the U.S. Sales split year +3 Total addressable 35% market 65% 1 424 854 hospitals 35 600 Main unit Disposables hospitals with with Level III and NICU
Slide 11: 10 leading children's hospitals with Level III or IV NICUs
10 leading children’s hospitals with Level III or IV NICUs Target customers for market launch Top 10 target pilot hospitals Pittsburgh Cincinnati Logo Boston SF Philadelphia LA Washington, DC Columbus Houston Neola Medical Source: Q2, 2024 American Hospital Directory *based on available American Hos
Slide 12: Neola will bring financial value to customers
Neola® will bring financial value to customers in the form of avoided costs and reduced length-of-stay Reduced length of stay in the NICU Reduced number of blood gas samples and chest x-rays Reduced manual observation time for nurses Potential reimbursement via MS-DRG payments Neola Medical Source:
Slide 13: Commercialization strategy and plan
Commercialization strategy and plan Reaching Milestones that Drive Value Creation 2021-2024 2025-2026 2027 -> Neola Medical Q2, 2024
Slide 14: Focus 2024
Focus 2024 Preparations for 1 Clinical validation 2 FDA process 3 market launch in the U.S 14 Neola Medical Q2, 2024
Slide 15: Significant events Q2 2024
Significant events Q2 2024 Obtianed CB certificate Achieved milstone that meets partial regulatory requirements for FDA approval Affirming the safety and performance of Neola® in neonatal intensive care units Strong testament to the effectiveness of our structured product development process 15 Neol
Slide 16: Significant events Q2 2024
Significant events Q2 2024 Concluded Human Factors Validation Study Usable and safe design Confirmed as safe for its intended use by healthcare professionals in neonatal intensive care Positive response from neonatal nurses for its clinical utility Favorable conditions for Neola® to be integrated ef
Slide 17: Significant events Q2 2024
Significant events Q2 2024 New recruitment ahead of market launch in the USA Comprehensive expertice Subsidary Neola Medical, Inc. Simplifies the establishment of on-site operations and management in the U.S. New Board Member New CFO Monica Alfaro David Folkesson Welling 17 Neola Medical Q2, 2024
Slide 18: Highlights half year of 2024
Highlights half year of 2024 Neola Medical receives support from Stanford Impact1 program, partly funded by FDA and Gates Foundation Neola® is selected as one of the most promising innovations in neonatal intensive care globally Exclusive network of experts from Stanford, FDA and leading neonatologi
Slide 19: Highlights half year of 2024
Highlights half year of 2024 Secured financing for 2024 Direct share issue at 11,5% premium on the share price (20 m SEK) Strengthening the company’s ownership base and long-term shareholder value Enables focus on clinical validation studies for the launch of Neola® Source: Avanza.se 19 Neola Medica
Slide 20: Financial summary
Financial summary 20 Neola Medical Q2, 2024
Slide 21: Financials
Financials Second quarter, April-June 2024 Half year report, January-June 2024 Operating result: SEK -3 011k (-2 586) Operating result: SEK -5 579k (-4 941) Operating expenses: SEK -5 372k (-4 784) Operating expenses: SEK -10 988k (-9 083) Cash flow for the period: SEK -6 034k (-4 508) Cash flow for
Slide 22: About the share
About the share Share capital, shareholders and the share 2024-06-30 Company value As of June 30th 2024 Neola Medical’s share capital was 5 010 751 SEK with a total of 70 150 234 shares. All shares are of the same type, have an equal right to a share in 250 000 000 the Company’s assets and profits a
Slide 23: Reaching Milestones that Drive Value Creation
Reaching Milestones that Drive Value Creation FDA application Neola® meets partial Positive clinical results Subsidiary in regulatory requirements from Irish independent the USA for FDA approval study of 100 newborns Clinical study on Technical verification preterm born babies Successful Human in th
Slide 24: Financial calendar and contact
Financial calendar and contact 6 12 9 21 Nov 2024 Feb 2025 April 2025 May 2025 Q3 report 2024 Year End Financial Annual report 2024 Q1 report 2025 and Annual Statement 2024 General Assembly Financial reports Questions about the report is answered by: Financial reports are available at www.neolamedic
Slide 25: Investment highlights
Investment highlights 1 Large and growing addressable market 2 Great clinical need and demand 3 Attractive business model 4 Proven technology 5 Highly experienced team 25 Neola Medical Q2, 2024
Slide 26: LinkedIn I Facebook I Website
LinkedIn I Facebook I Website Neola Medical Q2, 2024